NephrologyNow The Ultimate Guide to Kidney Disease Research

This review summarizes results of the landmark ESCAPE trial, which has shown that lowering the blood pressure target to below the 50th percentile slows pediatric chronic kidney disease progression.
document.getElementById(“post-1366-blankimage”).onload();

This interesting secondary analysis of the CHOIR trial demonstrates that patients achieving their assigned Hb target had better outcomes than those that did not achieve target.  Furthermore, those patients randomized to a higher Hb target, who actually reached that target, saw no increased risk.  This study raises the question whether it is the high dose [...]

This addition to the AJKD Core Curriculum series reviews “Toxic Nephropathies”.
document.getElementById(“post-1362-blankimage”).onload();

This indepth review looks at diabetic autonomic and peripheral neuropathy in patients with stages 4-5 CKD or ESRD undergoing dialysis. The evidence supporting the available therapeutic options and the challenges associated with providing adequate care as well as future directions for investigation are discussed.
document.getElementById(“post-1358-blankimage”).onload();

This editorial by Dr. Ajay Singh discusses the implications of TREAT in the context of the existing evidence base on the management of anemia due to chronic kidney disease.
document.getElementById(“post-1328-blankimage”).onload();

This NEJM clinical practice article highlights the management of chronic kidney disease with a look at supporting evidence and review of formal guidelines.
document.getElementById(“post-1326-blankimage”).onload();

This re-analysis of data from the North American Symptomatic Carotid Endarterectomy Trial showed that patients with stage 3 CKD and symptomatic high-grade carotid stenosis gained a large benefit in stroke risk reduction after endarterectomy.
Free full text access kindly provided by the American Society of Nephrology.
document.getElementById(“post-1318-blankimage”).onload();

The COOPERATE study had previously been looked upon as providing support for combination ACE inhibitor and ARB therapy in proteinuric patients with non-diabetic kidney disease. After an initial letter of concern, the Lancet has retracted the paper after the results of an academic investigation indicated serious concerns surrounding this publication.  These include that the trial had [...]

This paper demonstrates that among nursing home residents with ESRD, the initiation of dialysis is associated with a substantial and sustained decline in functional status.
document.getElementById(“post-1256-blankimage”).onload();

This randomized, double-blind, placebo-controlled trial compared a strategy of initiating darbepoetin alfa at a threshold hemoglobin of 11.0 g per deciliter, with a goal of 13 g per deciliter, versus placebo, with rescue darbepoetin alfa when Hb fell below 9.0 g per deciliter. Patients studied included those with diabetes, CKD (defined as GFR 20-60 ml/min) and anemia. No difference [...]

This editorial provides insight into the interpretation of the TREAT study, “A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease”.
document.getElementById(“post-1206-blankimage”).onload();

This podcast, produced by the American Society of Nephrology, discusses the pros and cons of eGFR measurement.
document.getElementById(“post-1195-blankimage”).onload();

This study shows that in a large, community-based cohort of patients (from the Kaiser Permanente database) with pre-existing normal or near normal kidney function, an episode of dialysis-requiring ARF was a strong independent risk factor for a long-term risk of progressive CKD and mortality.
document.getElementById(“post-1171-blankimage”).onload();